文献速递流行病学与生物统计临床试验与 GCP

多标志物适应性富集试验的推断

Inference for multimarker adaptive enrichment trials.
PubMed 文献 · Stat Med · 2017-08-10

针对缺乏单一治疗选择生物标志物的情况,适应性富集设计可在期中分析时调整入组标准。本文讨论在拒绝强零假设后,如何指定预期使用人群并估计其治疗效果,以及界定强零假设被拒绝即意味着预期使用人群零假设被拒绝的条件。

要点

  • 适应性富集设计允许在期中分析时调整入组标准以排除不太可能获益的患者。
  • 采用基于模型的多元特征预测分类器及连续生物标志物的优化切点。
  • 试验结束时对所有随机化患者进行单一显著性检验以检验强零假设。

核心结论

  • 本文讨论了适应性富集设计下推断的两个问题:拒绝强零假设后预期使用人群的指定及其治疗效应的估计,以及强零假设被拒绝即意味着预期使用人群零假设被拒绝的条件。

研究设计与样本

  • 方法学论文,考虑一种允许开发基于模型的多元特征预测分类器及连续生物标志物优化切点的灵活适应性富集设计方法。

主要发现

  • 试验结束时对所有随机化患者进行单一显著性检验,检验强零假设:在K个阶段 accrued 的任一患者亚群中,试验治疗的预期结局不优于对照。
  • 第一个问题涉及拒绝强零假设后预期使用人群的指定及该人群治疗效应的估计。
  • 第二个问题涉及定义强零假设被拒绝即意味着预期使用人群零假设被拒绝的条件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identification of treatment selection biomarkers has become very important in cancer drug development. Adaptive enrichment designs have been developed for situations where a unique treatment selection biomarker is not apparent based on the mechanism of action of the drug. With such designs, the eligibility rules may be adaptively modified at interim analysis times to exclude patients who are unlikely to benefit from the test treatment.We consider a recently proposed, particularly flexible approach that permits development of model-based multifeature predictive classifiers as well as optimized cut-points for continuous biomarkers. A single significance test, including all randomized patients, is performed at the end of the trial of the strong null hypothesis that the expected outcome on the test treatment is no better than control for any of the subset populations of patients accrued in the K stages of the clinical trial. In this paper, we address 2 issues involving inference following an adaptive enrichment design as described above. The first is specification of the intended use population and estimation of treatment effect for that population following rejection of the strong null hypothesis. The second issue is defining conditions in which rejection of the strong null hypothesis implies rejection of the null hypothesis for the intended use population.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Simon R, Simon N. Inference for multimarker adaptive enrichment trials. Stat Med. 2017. PMID: 28795420. doi:10.1002/sim.7422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。